SUBSCRIBE
SUBSCRIBE

Tvardi Therapeutics

IN THE PRESS
Press Releases
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024
October 2, 2024
 · 
1 min read
Business
Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors
March 26, 2024
 · 
2 min read
Lone Star Bio
Tvardi Therapeutics to Participate at the Cowen 44th Annual Health Care Conference
March 1, 2024
 · 
1 min read
Lone Star Bio
Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium
January 18, 2024
 · 
2 min read
Lone Star Bio
Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference
November 21, 2023
 · 
1 min read
JOBS